



NEWS RELEASE

US Army Partners with Defyrus Inc. to Evaluate DEF201's Enhancement of Biodefense Vaccine(s) Performance

Web Site Release

March 11, 2011

Toronto - Defyrus Inc. today announced the signing of a Collaborative Research and Development Agreement (CRADA) with the United States Army Medical Research Institute of Infectious Diseases (USAMRIID), Fort Detrick, Maryland to evaluate DEF201 "in alphaviral vaccine studies for the ability to enhance immunogenicity and protective efficacy of vaccine candidates". Under the terms of the CRADA, Defyrus will provide its immune stimulator drug candidates mDEF201 (adenoviral vectored mouse interferon alpha) and DEF201 (adenoviral vectored human consensus interferon alpha). USAMRIID will then utilize its established, well characterized in vivo aerosol challenge models to determine improvement to vaccine performance in terms of a) immunogenicity (ie more neutralizing antibodies and protective white blood cells) and b) protective efficacy (ie superior protection afforded animals challenged with test viruses).

"Improving host immune responses is the basis of our Aderon™ technical approach with our DEF201 drug candidate" stated, Dr. Jeffrey Turner, President & CEO, Defyrus Inc., "we welcome the independent evaluation of DEF201's performance by USAMRIID alongside their vaccine candidates".

About Defyrus Inc.

Defyrus is a private, life sciences biodefence company that collaborates with military and public health R&D partners in the United States, United Kingdom and Canada to develop broad spectrum anti-viral drugs and immune stimulator to improve vaccine performance as medical countermeasures to viral threats of military and public health interest. www.defyrus.com

About USAMRIID

USAMRIID's mission is to conduct basic and applied research on biological threats resulting in medical solutions (vaccines, drugs and diagnostics) to protect our Nation's armed forces, and its research often has applications that benefit society as a whole. As the lead military medical research laboratory for the Defense Threat Reduction Agency's Joint Science and Technology Office for Chemical and Biological Defense, USAMRIID plays a key role in national defense and in infectious disease research. USAMRIID is a subordinate laboratory of the U.S. Army Medical Research and Materiel Command.

[The information contained in this press release does not necessarily reflect the position or the policy of the Government and no official endorsement should be inferred.]

###



For further information:

Dr. Jeffrey D. Turner
President & CEO
Tel: (613) 674-1138
info@defyrus.com

Mr. Dana Rath
Chief Financial Officer
Tel: (514) 939-2531
info@defyrus.com